Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

1.

Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.

Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ; Dutch - Belgian HOVON cooperative group.

Br J Haematol. 2010 Jul;150(2):209-17. doi: 10.1111/j.1365-2141.2010.08227.x. Epub 2010 May 9.

PMID:
20507310
[PubMed - indexed for MEDLINE]
2.

A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.

Lozano M, Knutson F, Tardivel R, Cid J, Maymó RM, Löf H, Roddie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C.

Br J Haematol. 2011 May;153(3):393-401. doi: 10.1111/j.1365-2141.2011.08635.x. Epub 2011 Mar 21.

PMID:
21418180
[PubMed - indexed for MEDLINE]
3.

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.

van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L; euroSPRITE trial.

Blood. 2003 Mar 15;101(6):2426-33. Epub 2002 Nov 27.

PMID:
12456508
[PubMed - indexed for MEDLINE]
Free Article
4.
5.

Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.

Schlenke P, Hagenah W, Irsch J, Sundin D, Corash L, Lin L, Kirchner H, Wagner T.

Ann Hematol. 2011 Dec;90(12):1457-65. doi: 10.1007/s00277-011-1222-3. Epub 2011 Apr 19.

PMID:
21503644
[PubMed - indexed for MEDLINE]
6.

Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.

[No authors listed]

BioDrugs. 2003;17(1):66-8.

PMID:
12534321
[PubMed - indexed for MEDLINE]
7.

A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.

Diedrich B, Ringdén O, Watz E, Shanwell A.

Vox Sang. 2009 Oct;97(3):254-9. doi: 10.1111/j.1423-0410.2009.01197.x. Epub 2009 May 7.

PMID:
19508669
[PubMed - indexed for MEDLINE]
8.

Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.

van Rhenen DJ, Gulliksson H, Cazenave JP, Pamphilon D, Davis K, Flament J, Corash L.

Transfus Med. 2004 Aug;14(4):289-95.

PMID:
15285725
[PubMed - indexed for MEDLINE]
9.

Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.

Janetzko K, Lin L, Eichler H, Mayaudon V, Flament J, Klüter H.

Vox Sang. 2004 May;86(4):239-45.

PMID:
15144528
[PubMed - indexed for MEDLINE]
10.

Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.

Simonsen AC, Johansson PI, Conlan MG, Jacquet M, Lin JS, Junge K, Lin L, Sørensen H, Borregaard N, Flament J.

Transfusion. 2006 Mar;46(3):424-33.

PMID:
16533286
[PubMed - indexed for MEDLINE]
11.

Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.

Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG; SPRINT Study Group.

Transfusion. 2005 Dec;45(12):1864-75.

PMID:
16371039
[PubMed - indexed for MEDLINE]
12.

A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions.

Anderson NA, Gray S, Copplestone JA, Chan DC, Hamon M, Prentice AG, Johnson SA, Phillips M, van Waeg G, Oakhill A, Abeyasekera S, Pamphilon DH.

Transfus Med. 1997 Mar;7(1):33-9.

PMID:
9089983
[PubMed - indexed for MEDLINE]
13.

The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage.

Cardigan R, Sutherland J, Wadhwa M, Dilger P, Thorpe R.

Vox Sang. 2003 Jan;84(1):28-35.

PMID:
12542731
[PubMed - indexed for MEDLINE]
14.

A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.

Mirasol Clinical Evaluation Study Group.

Transfusion. 2010 Nov;50(11):2362-75. doi: 10.1111/j.1537-2995.2010.02694.x.

PMID:
20492615
[PubMed - indexed for MEDLINE]
15.

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG.

Blood. 2004 Sep 1;104(5):1534-41. Epub 2004 May 11.

PMID:
15138160
[PubMed - indexed for MEDLINE]
Free Article
16.

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma.

Kerkhoffs JL, Eikenboom JC, Schipperus MS, van Wordragen-Vlaswinkel RJ, Brand R, Harvey MS, de Vries RR, Barge R, van Rhenen DJ, Brand A.

Blood. 2006 Nov 1;108(9):3210-5. Epub 2006 Jul 6.

PMID:
16825492
[PubMed - indexed for MEDLINE]
Free Article
17.

Preparation of leucocyte-poor platelet concentrates from buffy coats. IV. Clinical evaluation.

Pietersz RN, Reesink HW, Huijgens PC, van Oers MH.

Vox Sang. 1988;55(3):129-32.

PMID:
3070936
[PubMed - indexed for MEDLINE]
18.

Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.

Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B.

Lancet. 2002 Jun 22;359(9324):2145-52.

PMID:
12090979
[PubMed - indexed for MEDLINE]
19.

Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials.

Cid J, Escolar G, Lozano M.

Vox Sang. 2012 Nov;103(4):322-30. doi: 10.1111/j.1423-0410.2012.01614.x. Epub 2012 May 7.

PMID:
22563850
[PubMed - indexed for MEDLINE]
20.

Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.

Sigle JP, Infanti L, Studt JD, Martinez M, Stern M, Gratwohl A, Passweg J, Tichelli A, Buser AS.

Transfusion. 2013 Aug;53(8):1788-97. doi: 10.1111/j.1537-2995.2012.03959.x. Epub 2012 Nov 26.

PMID:
23176347
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk